Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.

Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.